

Comparison between FEV₁/FEV₆ and FEV₁/FVC as screening of chronic obstructive pulmonary disease

Ng Seow Ching, MRCP, Mohd Faizul Bin Abu Samah, MRCP, Khaled Mohamed Helmy Abd El-Aziz, Egyptian Higher DP Speciality of Chest Diseases, Sia Koon Ket, Fellowship in Gastroenterology

Medical Department, Hospital Tuanku Fauziah, Jalan Kolam, Kangar, Perlis Indera Kayangan, Malaysia

ABSTRACT

Objective: To compare FEV₁/FEV₆ to the standard spirometry (FEV₁/FVC) as a screening tool for COPD.

Methods: This cross-sectional study was conducted at Hospital Tuanku Fauziah, Perlis, Malaysia from August 2015 to April 2016. FEV₁/FEV₆ and FEV₁/FVC results of 117 subjects were analysed. Demographic data and spirometric variables were tabulated. A scatter plot graph with Spearman's correlation was constructed for the correlation between FEV₁/FEV₆ and FEV₁/FVC. The sensitivity, specificity, positive and negative predictive values of FEV₁/FEV₆ were determined with reference to the gold standard of FEV₁/FVC ratio <0.70. Receiver-operator characteristic (ROC) curve analysis and Kappa statistics were used to determine the FEV₁/FEV₆ ratio in predicting an FEV₁/FVC ratio <0.70.

Results: Spearman's correlation with $r = 0.636$ ($P < 0.001$) was demonstrated. The area under the ROC curve was 0.862 (95% confidence interval [CI]: 0.779 - 0.944, $P < 0.001$). The FEV₁/FEV₆ cut-off with the greatest sum of sensitivity and specificity was 0.75. FEV₁/FEV₆ sensitivity, specificity, positive and negative predictive values were 93.02%, 67.74%, 88.89% and 77.78% respectively. There was substantial agreement between the two diagnostic cut-offs ($\kappa = 0.634$; 95% CI: 0.471 - 0.797, $P < 0.001$)

Conclusions: The FEV₁/FEV₆ ratio can be considered to be a good alternative to the FEV₁/FVC ratio for screening of COPD. Larger multicentre study and better education on spirometric techniques can validate similar study outcome and establish reference values appropriate to the population being studied.

KEY WORDS:

FEV₁/FEV₆, FEV₁/FVC, chronic obstructive pulmonary disease

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterised by persistent and progressive airflow limitation, and is associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. It is an important and still-increasing cause of morbidity and mortality worldwide and results in substantial burden to the health care economy.

In fact, COPD is projected to be the fourth leading cause of death worldwide by the year 2030.¹

The criteria for the diagnosis of COPD as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) remains the spirometric criterion of a post-bronchodilator fixed ratio of FEV₁/FVC <0.70. Patients whose spirometry confirm the diagnosis of COPD will go for combined assessment and one element of assessment is the airway limitation based on FEV₁ versus predicted values and will be further classified into (FEV₁ ≥80% predicted), GOLD 2 (50% ≤ FEV₁ <80% predicted), GOLD 3 (30% ≤ FEV₁ <50% predicted), and GOLD 4 (FEV₁ <30% predicted).¹ Unfortunately, spirometry is not widely available in most health care clinics in Malaysia. The sophistication of spirometers translates to a need for specialised technicians to perform the examination. Spirometry requires a prolonged exhalation time to achieve a plateau on the volume-time curve, and this can lead to exhaustion and possible syncope in test subjects.²

The National Lung Health Education Program recommended the use of FEV₁/FEV₆ for the detection of COPD in 2000.³ This statement was supported by several studies that concluded that FEV₁/FEV₆ has high sensitivity and specificity compared to the gold standard of FEV₁/FVC in the screening for COPD.⁴⁻¹⁷ The use of FEV₁/FEV₆ simplifies testing procedures and reduces test variability, which helps to improve its diagnostic accuracy.¹⁸ The criteria adopted by published studies to define obstruction from FEV₁/FEV₆ are variable. Several studies defined obstruction from FEV₁/FEV₆ based on lower limits of normality (LLN) developed from the third National Health and Nutrition Examination Survey (NHANES III) reference equations.^{4,9,10,12} These reference equations are influenced by age, sex, height and ethnicity and are currently available only for the USA population (NHANES III survey)¹⁹ and for European subjects in the 65 to 85 years age group.²⁰ Other studies used the sensitivity and specificity values associated with receiver operator characteristic (ROC) curve analysis to find the best cut-off point for FEV₁/FEV₆ comparable to GOLD FEV₁/FVC fixed ratio of <0.70.^{5,13-17}

OBJECTIVE

To demonstrate the reliability of FEV₁/FEV₆ as a screening tool for COPD in general practice compared to the standard spirometry which is FEV₁/FVC.

This article was accepted: 8 October 2017

Corresponding Author: Ng Seow Ching

Email: xuiayushiching@gmail.com

MATERIALS AND METHODS

Study Design and Subjects

This was a cross-sectional study conducted from August 2015 to April 2016. A total of 117 subjects referred to Chest Clinic, Hospital Tuanku Fauziah for spirometry from Medical Outpatient Department (MOPD) and health care clinics to confirm the diagnosis of COPD were recruited into the study. The inclusion criteria were age more than 40 years old; history of dyspnoea that was progressive, persistent and characteristically worsened with exercise; history of chronic cough (may be intermittent or unproductive); history of chronic sputum production of any kind; history of exposure to risk factors (tobacco smoke, smoke from home cooking and heating fuels, occupational dusts and chemicals); and any smoker even in the absence of above symptoms. Subjects who were contraindicated for spirometry as per American Thoracic Society/European Respiratory Society recommendations² and subjects who were anticipated to be unable to perform six forced blows as presumed by the spirometry technician were excluded from the study. This study was registered with National Medical Research Register with the reference number of NMRR-15-963-26480 (IIR) and was approved by Medical Research & Ethics Committee, Ministry of Health, Malaysia.

Instruments

COPD-6 is a small portable electronic device that is powered by two disposable batteries. It has a large easy-to-read display and can display on a colour scale the degree of airway obstruction according to the GOLD classification. The device also has an automatic test quality alert that detects errors such as premature ending of the manoeuvre or cough. The device requires only minimal instruction for use by non-respiratory specialists.²¹ The COPD-6 device was checked for calibration errors before the start of the study by the investigators. Before taking any readings with the device, the trained staff entered patient's data including age, sex, height and weight. Height was measured to the nearest centimetre without shoes and weight was recorded to the nearest kilogram. Three post-bronchodilator readings (i.e., 15 minutes after the application of 400mcg of aerosolised salbutamol via a spacer) were taken. The highest FEV₁ and FEV₆ value of the three post-bronchodilator measurements was used and the FEV₁/FEV₆ ratio was calculated.

Conventional spirometry was performed with a PC-based SpiroPerfect Spirometer (Welch Allyn, New York, NY, USA) by highly trained and experienced technicians in accordance with American Thoracic Society criteria.²² The spirometer was calibrated daily using a 3L syringe. The spirometry tests obtained were analysed by the investigators for their quality and acceptability. Three acceptable and reproducible manoeuvres were performed in each test, and the spirometric measurements with the highest FEV₁/FVC ratio were chosen for final analysis. A post-bronchodilator fixed ratio of FEV₁/FVC <0.70 was used as criteria for the diagnosis of COPD as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).¹

Statistical Analysis

Sample size calculation was done using Raosoft Sample Size Calculator version 2004 (<http://www.raosoft.com/samplesize.html>). With a margin of error of 8%, a confidence level of 90%, a response distribution of 50%, and to account for 10% drop outs, a total sample size of 117 subjects was enrolled for this study. Demographic data was tabulated using Microsoft Excel 2007 (Microsoft Corp). Age, height, weight, smoking pack years and years of environmental/occupational exposure were reported as means \pm SD. A scatter plot graph was constructed and Spearman's correlation was used to study the correlation between FEV₁/FEV₆ and FEV₁/FVC. The performance of the FEV₁/FEV₆ was analysed using two-by-two tables, to determine the sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV). Receiver operator characteristic (ROC) curve analysis was performed to measure the accuracy of FEV₁/FEV₆ in comparison with FEV₁/FVC, and to identify the FEV₁/FEV₆ cut-off that had the greatest sum of sensitivity and specificity for the diagnosis of COPD as defined by FEV₁/FVC ratio <0.70. The agreement between FEV₁/FEV₆ and FEV₁/FVC was also calculated using Kappa statistics. All analyses were performed using Statistical Package for the Social Sciences (SPSS v23).

RESULTS

Of the total 117 subjects, 86.3% were males and 13.7% were females. The majority of subjects were Malays (88%). Smoking status analysis revealed that 41% of subjects were current smokers, 47.9% were former smokers, 1.7% was never smokers, and 9.4% had history of environmental/occupational exposure to risk factors (mainly exposure to home cooking and heating fuels, with one of the subject being a worker in curtain production industry). Subject characteristics and mean spirometric results are shown in Table I.

Before the analysis of accuracy, a scatter plot graph between FEV₁/FEV₆ and FEV₁/FVC ratios was constructed, and Spearman's correlation with $r = 0.636$ ($P < 0.001$) was found (Figure 1).

Considering FEV₁/FVC ratio <0.70 as being the gold standard to diagnose COPD, a receiver operator characteristic (ROC) curve was constructed to determine the best corresponding cut-off for FEV₁/FEV₆ (Figure 2). The area under the ROC curve was 0.862 (95% confidence interval (CI): 0.779 to 0.944, $P < 0.001$). The FEV₁/FEV₆ cut-off, corresponding to the greatest sum of sensitivity and specificity, was 0.75. For the study group, the FEV₁/FEV₆ sensitivity was 93.02% and specificity was 67.74%. The PPV of FEV₁/FEV₆ was 88.89%, and the NPV was 77.78% (Table II). Diagnostic accuracy of FEV₁/FEV₆ across different cut-off points was shown in Table III. As the cut-off point was lowered, FEV₁/FEV₆ became less sensitive but more specific, the PPV increased, and the NPV decreased.

Table I: Characteristics of the Study Group

Characteristic	Values
Age (years; mean ± SD)	67.38 ± 11.58
Male (%)	86.3
Ethnicity (%)	
Malay	88
Chinese	9.4
Siamese	2.6
Weight (kg; mean ± SD)	60.79 ± 14.21
Height (cm; mean ± SD)	159.18 ± 7.68
Smoking Status (%)	
Current Smoker	41
Former Smoker	47.9
Never Smoker	1.7
Environmental/Occupational Exposure	9.4
Pack-Years (mean ± SD)	37.97 ± 14.51
Pack-Year Categories (%)	
1 – 14	5
15 – 24	18
25 – 49	52
50+	25
FEV ₁ /FVC (%; mean ± SD)	57.37 ± 16.44
FEV ₁ /FEV ₆ (%; mean ± SD)	61.70 ± 17.00

Table II: Comparison of FEV₁/FEV₆ with FEV₁/FVC for the Diagnosis of COPD

FEV ₁ /FEV ₆	FEV ₁ /FVC		Total
	< 70%	≥ 70%	
< 75%	80	10	90
≥ 75%	6	21	27
Total	86	31	117

Sensitivity: 93.02%; specificity: 67.74%; positive predictive value: 88.89%; negative predictive value: 77.78%; using FEV₁/FVC <70% as a fixed cut-off; using FEV₁/FEV₆ <75% as a fixed cut-off.

Table III: Diagnostic Accuracy of FEV₁/FEV₆ across Different Cut-Off Points. PPV: Positive Predictive Value; NPV: Negative Predictive Value

FEV ₁ /FEV ₆ (%)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
< 70	80.23	77.42	90.79	58.54
< 73	87.21	70.97	89.29	66.67
< 75	93.02	67.74	88.89	77.78
< 78	94.19	64.52	88.04	80.00
< 80	96.51	54.84	85.57	85.00

Overall agreement between FEV₁/FEV₆ and FEV₁/FVC was assessed using kappa statistics. A kappa value of 0.634 (95% CI = 0.471 – 0.797, P < 0.001) was obtained, indicating substantial agreement between FEV₁/FEV₆ and FEV₁/FVC.




Fig. 1: Correlation between FEV₁/FEV₆ and FEV₁/FVC.




Fig. 2: Receiver operator characteristic (ROC) curve for FEV₁/FEV₆ using FEV₁/FVC ratio < 0.70 as gold standard to diagnose COPD. Area under the ROC curve = 0.862 (95% confidence interval: 0.779 – 0.944, P < 0.001).

DISCUSSION

FEV₆ has already been demonstrated to be a reliable alternative for FVC in identifying obstructive and restrictive spirometric patterns, using the NHANES III reference equations to calculate LLN for each spirometric index.^{4,7} However, these studies were limited by using only pre-bronchodilator values and the study samples only contained Caucasians. Besides, reference equations developed from NHANES III are currently available only for the USA population.¹⁹ Garcia-Rio F et al.²⁰ had also published spirometric reference equations for European subjects aged 65 to 85 years old. There is currently no available spirometric reference equations developed for use in Asian population.

Several studies examined the possibility of establishing a fixed cut-off for FEV₁/FEV₆ that corresponds to the GOLD FEV₁/FVC fixed ratio of <0.70.^{5,13-17} The advantage of using a fixed cut-off value for the FEV₁/FEV₆ ratio to diagnose airway obstruction was highlighted by the main COPD guidelines.^{3,23} Four studies showed a similar cut-off point (0.73) of the FEV₁/FEV₆ ratio for the detection of airway obstruction.^{13-15,17} Two other studies however showed another similar cut-off point (0.75) of the FEV₁/FEV₆ ratio.^{5,16} Our study showed that the best cut-off for FEV₁/FEV₆ was 0.75, corresponded to the studies by Rosa FW et al.⁵ and P. Frith et al.¹⁶ While fixed cut-off values are more widely used, there is potential for misclassification, as spirometric indices are highly influenced by age, sex, race and height. For example, elderly subjects typically show an age-related decline in FEV₁/FVC and FEV₁/FEV₆, causing a significant over-diagnosis of airway obstruction.²⁴ Thus, fixed cut-off values should be used with caution, particularly outside the middle-aged population.

The use of six-second expiratory manoeuvres provide several advantages over measurements of FVC in the elderly and in primary care.^{3,18} FEV₆ is less demanding for patients as patients do not have to force expire through a 15- to 20-second period, thus making the manoeuvre more easily achievable especially in the elderly and impaired patients. The shorter expiratory times require less data storage space, hence the ability to develop smaller and portable spirometers which is convenient for use in primary care setting. In addition, despite minimal instructions provided to non-respiratory specialists, these expiratory flow meters have high accuracy and reliability in the detection of airflow obstruction. This can facilitate the identification and referral of patients who are likely to benefit from formal spirometric evaluation in specialised respiratory institutions.

Our study showed a sensitivity of 93.02% but specificity of 67.74%, using the fixed cut-off FEV₁/FEV₆ <0.75. The kappa agreement between FEV₁/FEV₆ and FEV₁/FVC in our study was 0.634, indicating only substantial agreement between the two tests. Analysis of the discordant cases showed that there were discrepancies in the subjects' techniques in performing on the COPD-6 and conventional spirometer. Hence, we felt that more education can be given to patients on the proper techniques of performing on the COPD-6 and conventional spirometer. As our study was a pilot study involving only a small number of subjects, this may not represent the whole Malaysian COPD population and we recommend that larger scale study involving specialised respiratory institutions and

primary care centers to be conducted in Malaysia, so as to get a more accurate outcome of study that better reflect our local context.

CONCLUSION

We thereby conclude that FEV₁/FEV₆ fixed ratio can be considered a good alternative to FEV₁/FVC ratio in the screening of COPD. Better education to patients on proper respiratory manoeuvres and larger multi-centre studies are required to validate similar study outcome and to establish reference values that are technically and biologically appropriate to the population being studied.

ACKNOWLEDGEMENTS

We would like to thank the Director General of Health Malaysia for his permission to publish this paper.

REFERENCES

1. Global Strategy for Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016 [Updated Dec 2015, cited July 2016]. Available from: <http://www.goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/>.
2. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R et al. General considerations for lung function testing. *Eur Respir J* 2005; 26(1): 153-61.
3. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. *Chest* 2000; 117(4): 1146-61.
4. Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno LA, Crapo RO. FEV₆ is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. *Am J Respir Crit Care Med* 2000; 162(3 Pt 1): 917-9.
5. Rosa FW, Perez-Padilla R, Camelier A, Nascimento OA, Menezes AM, Jardim JR et al. Efficacy of the FEV₁/FEV₆ ratio compared to the FEV₁/FVC ratio for the diagnosis of airway obstruction in subjects aged 40 years or over. *Braz J Med Biol Res* 2007; 40(12): 1615-21.
6. Enright PL, Connett JE, Bailey WC. The FEV₁/FEV₆ predicts lung function decline in adult smokers. *Respir Med* 2002; 96(6): 444-9.
7. Vandevoorde J, Verbanck S, Schuermans D, Kartounian J, Vincken W. FEV₁/FEV₆ and FEV₆ as an alternative for FEV₁/FVC and FVC in the spirometric detection of airway obstruction and restriction. *Chest* 2005; 127(5): 1560-4.
8. Lundgren FL, Cabral MM, Climaco DC, de Macedo LG, Coelho Mde A, Dias AL. Determination of the efficacy of FEV₆ as a surrogate for FVC in the diagnostic screening for chronic obstructive pulmonary disease through the comparison of FEV₁/FVC and FEV₁/FEV₆ ratios. *J Bras Pneumol* 2007; 33(2): 148-51.
9. Lamprecht B, Schirmer L, Tiefenbacher F, Kaiser B, Buist SA, Studnicka M et al. Six-second spirometry for detection of airway obstruction: a population-based study in Austria. *Am J Respir Crit Care Med* 2007; 176(5): 460-4.
10. Akpinar-Elci M, Fedan KB, Enright PL. FEV₆ as a surrogate for FVC in detecting airways obstruction and restriction in the workplace. *Eur Respir J* 2006; 27(2): 374-7.
11. Gleeson S, Mitchell B, Pasquarella C, Reardon E, Falsone J, Berman L. Comparison of FEV₆ and FVC for detection of airway obstruction in a community hospital pulmonary function laboratory. *Respir Med* 2006; 100(8): 1397-1401.
12. Perez-Padilla R, Wehrmeister FC, Celli BR, Lopez-Vrelva MV, Montes de Oca M, Muino A et al. Reliability of FEV₁/FEV₆ to Diagnose Airflow Obstruction Compared with FEV₁/FVC: The PLATINO Longitudinal Study. *PLoS ONE* 8(8): e67960.
13. Vandevoorde J, Verbanck S, Schuermans D, Kartounian J, Vincken W. Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV₁/FEV₆ and FEV₆. *Eur Respir J* 2006; 27(2): 378-83.
14. Melbye H, Medbo A, Crockett A. The FEV₁/FEV₆ ratio is a good substitute for the FEV₁/FVC ratio in the elderly. *Prim Care Respir J* 2006; 15(5): 294-8.

15. Kumar Singh A, Lohia A. FEV1/FEV6: a reliable, easy-to-use, and cheaper alternative to FEV1/FVC in diagnosing airway obstruction in Indian population. *ISRN Pulmonology*. Volume 2012 (2012):109295.
16. P. Frith, Crockett A, Beilby J, Marshall D, Attewell R, Ratnanesan A et al. Simplified COPD Screening: Validation of the PiKo-6® in Primary Care. *Prim Care Respir J* 2011; 20(2): 190-8.
17. Bhatt SP, Kim YI, Wells JM, Bailey WC, Ramsdell JW, Foreman MG et al. FEV1/FEV6 to diagnose airflow obstruction: comparisons with computed tomography and morbidity indices. *Ann Am Thorac Soc* 2014; 11(3): 335-41.
18. Jing JY, Huang TC, Cui W, Xu F, Shen HH. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. *Chest* 2009; 135(4): 991-8.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S population. *Am J Respir Crit Care Med* 1999; 159(1): 179-87.
20. Garcia-Rio F, Pino JM, Dorgham A, Alonso A, Villamor J. Spirometric reference equations for European females and males aged 65–85 yrs. *Eur Respir J* 2004; 24(3): 397-405.
21. Vitalograph® Your cardio-respiratory partner [Cited July 2016]. Available from: <https://vitalograph.co.uk/product/161419/copd-6>.
22. American Thoracic Society. Standardization of spirometry, 1994 update. *Am J Respir Crit Care Med* 1995; 152(3): 1107-36.
23. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004; 23(6): 932-46.
24. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. *Eur Respir J* 2002; 20(5): 1117-22.